Saint-Jean-Pied-de-Port (FR)
{name}
{subtitle}
A Study of Imlunestrant, Investigator's Choice of Endocrine Therapy, and Imlunestrant Plus Abemaciclib in Participants With ER+, HER2- Advanced Breast Cancer
city
~34 mi. (Bayonne, France, +192 more cities)
facility
Centre Hospitalier de la Côte Basque
biomarker
ER Positive, +1 more biomarker
condition
Breast Carcinoma
drug
abemaciclib, +1 more drug
drug type
hormone therapy, +1 more type
A Study of Oral Venetoclax Tablets and Oral Azacitidine Versus Oral Azacitidine as Maintenance Therapy in Adult Participants With Acute Myeloid Leukemia in First Remission After Conventional Chemotherapy
city
~34 mi. (Bayonne, France, +197 more cities)
facility
Centre Hospitalier de la Cote /ID# 216185
biomarker
BCR-ABL1 Fusion, +47 more biomarkers
condition
Acute Myeloid Leukemia
drug
azacitidine, +1 more drug
drug type
chemotherapy
A Study of Abiraterone Acetate Plus Prednisone With or Without Abemaciclib (LY2835219) in Participants With Prostate Cancer
city
~34 mi. (Bayonne, France, +107 more cities)
facility
Centre Hospitalier de la Côte Basque
condition
Prostate Adenocarcinoma
drug
abemaciclib, +2 more drugs
drug type
hormone therapy, +1 more type
A Study Evaluating the Efficacy and Safety of Adjuvant Giredestrant Compared With Physician's Choice of Adjuvant Endocrine Monotherapy in Participants With Estrogen Receptor-Positive, HER2-Negative Early Breast Cancer (lidERA Breast Cancer)
city
~42 mi. (Pamplona, Spain, +89 more cities)
facility
Complejo Hospitalario de Navarra; Servicio de Farmacia
biomarker
ER Positive, +1 more biomarker
condition
Breast Carcinoma
drug
giredestrant, +1 more drug
drug type
hormone therapy
Sasanlimab (PF-06801591) in Combination With BCG or as Single Agent in Participants With High-Risk Non-Muscle Invasive Bladder Cancer
city
~42 mi. (Pamplona, Spain, +153 more cities)
facility
Complejo Hospitalario de Navarra
condition
Bladder Urothelial Carcinoma, +2 more conditions
drug
BCG solution, +1 more drug
drug type
immunotherapy